Meghan M. Joly
YOU?
Author Swipe
View article: Statins for polycystic ovary syndrome in varying resource settings: a phenome-wide association study and evidence synthesis
Statins for polycystic ovary syndrome in varying resource settings: a phenome-wide association study and evidence synthesis Open
Background There are many diseases prevalent around the globe that lack accessible and safe treatment options. Through Vanderbilt University Medical Center’s and Repurposing Essential Medicines Internationally program (Project Remedi), we …
View article: Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse model
Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse model Open
Pancreatic ductal adenocarcinoma (PDAc) is a deadly malignancy, most commonly diagnosed in advanced stages when no curative treatments are available. The development of new models that aid ongoing investigation into the mechanisms by which…
View article: The circulating renin-angiotensin system and mortality among patients hospitalized for COVID-19: a mechanistic substudy of the ACTIV-4 Host Tissue trials
The circulating renin-angiotensin system and mortality among patients hospitalized for COVID-19: a mechanistic substudy of the ACTIV-4 Host Tissue trials Open
We measured circulating components of the renin-angiotensin system (RAS) longitudinally over 5 days among patients hospitalized with COVID-19 and new-onset hypoxemia. We found that higher serum angiotensin-converting enzyme (ACE)-2 protein…
View article: Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia
Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia Open
Fostamatinib, a spleen tyrosine kinase inhibitor, has been reported to improve outcomes of COVID-19. To evaluate the efficacy and safety of fostamatinib in adults hospitalized with COVID-19 and hypoxemia. This multicenter, phase 3, placebo…
View article: Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia
Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia Open
Importance Fostamatinib, a spleen tyrosine kinase inhibitor, has been reported to improve outcomes of COVID-19. Objective To evaluate the efficacy and safety of fostamatinib in adults hospitalized with COVID-19 and hypoxemia. Design, Setti…
View article: Repurposing N-acetylcysteine for management of non-acetaminophen induced acute liver failure: an evidence scan from a global health perspective
Repurposing N-acetylcysteine for management of non-acetaminophen induced acute liver failure: an evidence scan from a global health perspective Open
This body of literature indicates efficacy and safety of NAC in non-acetaminophen induced ALF. Given the presence of NAC on the EML, this medication is likely to be available across a range of resource settings; promulgating its use in thi…
View article: Taking AIM at serious illness: implementing an access to investigational medicines expanded access program
Taking AIM at serious illness: implementing an access to investigational medicines expanded access program Open
When seriously ill patients have exhausted all treatment options available as part of usual care, the use of investigational agents may be warranted. Food and Drug Administration’s (FDA) Expanded Access (EA) pathway provides a mechanism fo…
View article: Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19
Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19 Open
Importance Preclinical models suggest dysregulation of the renin-angiotensin system (RAS) caused by SARS-CoV-2 infection may increase the relative activity of angiotensin II compared with angiotensin (1-7) and may be an important contribut…
View article: Figure S3 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study
Figure S3 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study Open
Flow chart depicting the decision making steps towards selecting TBXA2R as a potential therapeutic target for drug repurposing of CPI211.
View article: Figure S2 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study
Figure S2 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study Open
The effect of U46619 and CPI211 on migration and invasion of 4T1 and MDA-MB-231 tumor cells through Matrigel-coated transwells was assessed. Tumor cells were seeded in the upper chambers of a Matrigel-coated transwell insert in serum-free …
View article: Data from Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade
Data from Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade Open
An estimated 40,000 deaths will be attributed to breast cancer in 2016, underscoring the need for improved therapies. Evading cell death is a major hallmark of cancer, driving tumor progression and therapeutic resistance. To evade apoptosi…
View article: Supplementary Figures S3 and S4 from Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade
Supplementary Figures S3 and S4 from Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade Open
S3. Representative images of cells grown in 3D Matrigel for 14D and treated with ABT-263 (1.0 uM). S4. Whole cell lysates from cells treated with ABT-263 (1.0uM) for 0=24 hours.
View article: Data from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study
Data from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study Open
Although new drug discoveries are revolutionizing cancer treatments, repurposing existing drugs would accelerate the timeline and lower the cost for bringing treatments to cancer patients. Our goal was to repurpose CPI211, a potent and sel…
View article: Figure S1 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study
Figure S1 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study Open
Chemical structure of CPI211 is shown in Panel A. Western analysis of 293T cells expressing lentiviral empty vector, TPr-WT, or TPr-T399A s shown in Panel B. Antibodies used are shown to the left of each panel.
View article: Data from Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade
Data from Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade Open
An estimated 40,000 deaths will be attributed to breast cancer in 2016, underscoring the need for improved therapies. Evading cell death is a major hallmark of cancer, driving tumor progression and therapeutic resistance. To evade apoptosi…
View article: Data from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study
Data from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study Open
Although new drug discoveries are revolutionizing cancer treatments, repurposing existing drugs would accelerate the timeline and lower the cost for bringing treatments to cancer patients. Our goal was to repurpose CPI211, a potent and sel…
View article: Figure S1 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study
Figure S1 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study Open
Chemical structure of CPI211 is shown in Panel A. Western analysis of 293T cells expressing lentiviral empty vector, TPr-WT, or TPr-T399A s shown in Panel B. Antibodies used are shown to the left of each panel.
View article: Supplementary Figures S3 and S4 from Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade
Supplementary Figures S3 and S4 from Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade Open
S3. Representative images of cells grown in 3D Matrigel for 14D and treated with ABT-263 (1.0 uM). S4. Whole cell lysates from cells treated with ABT-263 (1.0uM) for 0=24 hours.
View article: Supplemental Table S1 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study
Supplemental Table S1 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study Open
Supplemental Table S1. Kaplan-Meier analysis of clinical cancer expression datasets (RNA-Seq) to assess the relationship between disease free patient survival and TBXA2R expression levels, as determined using Kmplot.com software, using the…
View article: Supplementary Figures S1 and S2 from Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade
Supplementary Figures S1 and S2 from Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade Open
S1. CCLE-curated cancer cells were grouped according to tumor type and assessed for miRNA expression for BCL2 and BCL2L1 (Bcl-xL) using cBio portal (www.cbio.org). S2. Whole cell lysates form a panel of breast cancer cell lines were assess…
View article: Supplementary Figures S1 and S2 from Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade
Supplementary Figures S1 and S2 from Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade Open
S1. CCLE-curated cancer cells were grouped according to tumor type and assessed for miRNA expression for BCL2 and BCL2L1 (Bcl-xL) using cBio portal (www.cbio.org). S2. Whole cell lysates form a panel of breast cancer cell lines were assess…
View article: Supplemental Table S1 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study
Supplemental Table S1 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study Open
Supplemental Table S1. Kaplan-Meier analysis of clinical cancer expression datasets (RNA-Seq) to assess the relationship between disease free patient survival and TBXA2R expression levels, as determined using Kmplot.com software, using the…
View article: Figure S3 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study
Figure S3 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study Open
Flow chart depicting the decision making steps towards selecting TBXA2R as a potential therapeutic target for drug repurposing of CPI211.
View article: Figure S2 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study
Figure S2 from Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study Open
The effect of U46619 and CPI211 on migration and invasion of 4T1 and MDA-MB-231 tumor cells through Matrigel-coated transwells was assessed. Tumor cells were seeded in the upper chambers of a Matrigel-coated transwell insert in serum-free …
View article: Supplemental Figures from Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i>-Amplified Breast Cancers
Supplemental Figures from Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i>-Amplified Breast Cancers Open
Supplemental Figure S1. Kaplan meier analysis and oncoprint mapping of Luminal A/B (A) and Basal-like (B) TCGA-curated breast cancers, showing the tumors in each set with upregulation of Akt1/2/3 mRNA (red boxes) or phospho-S473 (black arr…
View article: Data from Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i>-Amplified Breast Cancers
Data from Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i>-Amplified Breast Cancers Open
HER2 overexpression drives Akt signaling and cell survival and HER2-enriched breast tumors have a poor outcome when Akt is upregulated. Akt is activated by phosphorylation at T308 via PI3K and S473 via mTORC2. The importance of PI3K-activa…
View article: Supplemental Figures from Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i>-Amplified Breast Cancers
Supplemental Figures from Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i>-Amplified Breast Cancers Open
Supplemental Figure S1. Kaplan meier analysis and oncoprint mapping of Luminal A/B (A) and Basal-like (B) TCGA-curated breast cancers, showing the tumors in each set with upregulation of Akt1/2/3 mRNA (red boxes) or phospho-S473 (black arr…
View article: Data from Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i>-Amplified Breast Cancers
Data from Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i>-Amplified Breast Cancers Open
HER2 overexpression drives Akt signaling and cell survival and HER2-enriched breast tumors have a poor outcome when Akt is upregulated. Akt is activated by phosphorylation at T308 via PI3K and S473 via mTORC2. The importance of PI3K-activa…
View article: Data from Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival
Data from Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival Open
Small-molecule inhibitors of the mTORC2 kinase (torkinibs) have shown efficacy in early clinical trials. However, the torkinibs under study also inhibit the other mTOR-containing complex mTORC1. While mTORC1/mTORC2 combined inhibition may …
View article: Supplemental Information from Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival
Supplemental Information from Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival Open
Supplemental Figures S1-9 Supplemental Figure S1 - Table of Oligos Supplemental Figures S2-5 - Scheme of chemical synthesis and characterization of polymers Supplemental Figure S6 - Basic in vitro characterization of si-NPs Supplemental Fi…